News

Interim phase 3 trial results showed an increased risk of death for patients receiving venetoclax for multiple myeloma.
Although there have been links between esophageal cancer and drinking hot tea, this was the first study to examine a specific temperature.
A phase 3 study compared overall survival and cardiac safety between biosimilar trastuzumab (Ontruzant) and the reference medicine.
Top news of the week from Specialty Pharmacy Times.
Top news of the day from across the health care industry.
Patients with multiple sclerosis who consumed 2 cans of soda per day were 5 times more likely to experience severe disability.
Solriamfetol (Sunosi, Jazz Pharmaceuticals) is the first dual-acting dopamine and norepinephrine reuptake inhibitor approved for this indication.

Product News

Granix is a human granulocyte factor produced in a bioreactor using recombinant DNA technology.
Complera treats HIV infection in previously untreated adults with a viral load of 100,000 copies/mL or less.
Repatha (evolocumab) treats primary hyperlipidemia in combination with dietary measures and maximally tolerated doses of statins.
Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) is approved for treatment of HIV-1 infection.

Most Popular

Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$